Complete Genomics and SOPHiA GENETICS Partner to Enhance Precision Medicine Through AI Analytics
In a significant move to advance precision medicine, Complete Genomics, a leader in genomic sequencing, has entered into a partnership with SOPHiA GENETICS, a renowned name in AI-driven healthcare solutions. The announcement was made during the Association for Molecular Pathology (AMP) Annual Meeting in Boston, highlighting the importance of this collaboration in the evolving landscape of genomics and cancer treatment.
This partnership will leverage SOPHiA GENETICS' innovative applications, MSK-ACCESS® and MSK-IMPACT®, which utilize artificial intelligence through the SOPHiA DDM™ platform. This technology is designed to enhance the capabilities of Complete Genomics' DNBSEQ-T1+ sequencing platform, offering advanced and precise solutions for both liquid biopsies and solid tumors. By integrating these state-of-the-art applications, the two companies aim to create a comprehensive and efficient sample-to-report workflow tailored for laboratories worldwide.
The DNBSEQ-T1+ platform brings a new level of accuracy and efficiency to laboratories, boasting Q40-level precision with the capability to process between 500 million to 2 billion reads per flow cell. Each run can deliver results in just 24 hours, making it a viable option for labs looking to meet the growing demand for high-quality cancer genomic profiling. This innovation is expected to empower decentralized laboratories to provide faster and more accurate insights for clinicians and researchers alike.
Rob Tarbox, vice president of product and marketing at Complete Genomics, emphasized that combining MSK’s validated assays with SOPHiA GENETICS’ robust analytics and their sequencing technology creates a potent solution for laboratories. This collaborative effort not only enhances the quality of cancer genomic profiling but also ensures that the insights derived are more affordable and accessible to a wider audience.
Every detail of this integration reflects a shared commitment to democratizing access to precision medicine, according to Ross Muken, President of SOPHiA GENETICS. He stated that their partnership with Complete Genomics is a strategic move to make groundbreaking genomic solutions scalable and available to laboratories globally. This approach is aimed at reinforcing the utilization of data-driven medicine, particularly in oncology, where timely and accurate diagnostics are crucial.
In terms of technological advancements, SOPHiA DDM™ acts as a technology-agnostic platform, which means it has the capability to standardize and analyze healthcare data from various sources. The collaborative evaluation of MSK-IMPACT® and MSK-ACCESS® on the DNBSEQ-T1+ platform revealed impressive concordance with other sequencing systems, achieving high alignment in variant calls and allele frequencies, while also minimizing background noise and reducing turnaround times.
The implications of this partnership extend far beyond technological enhancement; it signifies a leap toward promoting comprehensive genomic profiling pathways suitable for clinical laboratories and cancer centers worldwide. As this collaboration unfolds, it promises to not only enrich the capabilities of health institutions but also support drug developers in their quest for innovative treatments.
For those attending the AMP Annual Meeting from November 11–15, 2025, there will be opportunities to learn more about these revolutionary tools and insights at the Complete Genomics Booth 1210 and SOPHiA GENETICS Booth 921. Further information is also available through their respective websites, where they outline their full range of services and technological offerings.
This partnership is more than just a technical alliance; it's a powerful step toward reshaping precision medicine. With the integration of AI-driven analytics and cutting-edge genomic sequencing, Complete Genomics and SOPHiA GENETICS are paving the way for a future where precision oncology is accessible globally, heralding a new era in patient care and cancer treatment strategies.
This partnership will leverage SOPHiA GENETICS' innovative applications, MSK-ACCESS® and MSK-IMPACT®, which utilize artificial intelligence through the SOPHiA DDM™ platform. This technology is designed to enhance the capabilities of Complete Genomics' DNBSEQ-T1+ sequencing platform, offering advanced and precise solutions for both liquid biopsies and solid tumors. By integrating these state-of-the-art applications, the two companies aim to create a comprehensive and efficient sample-to-report workflow tailored for laboratories worldwide.
The DNBSEQ-T1+ platform brings a new level of accuracy and efficiency to laboratories, boasting Q40-level precision with the capability to process between 500 million to 2 billion reads per flow cell. Each run can deliver results in just 24 hours, making it a viable option for labs looking to meet the growing demand for high-quality cancer genomic profiling. This innovation is expected to empower decentralized laboratories to provide faster and more accurate insights for clinicians and researchers alike.
Rob Tarbox, vice president of product and marketing at Complete Genomics, emphasized that combining MSK’s validated assays with SOPHiA GENETICS’ robust analytics and their sequencing technology creates a potent solution for laboratories. This collaborative effort not only enhances the quality of cancer genomic profiling but also ensures that the insights derived are more affordable and accessible to a wider audience.
Every detail of this integration reflects a shared commitment to democratizing access to precision medicine, according to Ross Muken, President of SOPHiA GENETICS. He stated that their partnership with Complete Genomics is a strategic move to make groundbreaking genomic solutions scalable and available to laboratories globally. This approach is aimed at reinforcing the utilization of data-driven medicine, particularly in oncology, where timely and accurate diagnostics are crucial.
In terms of technological advancements, SOPHiA DDM™ acts as a technology-agnostic platform, which means it has the capability to standardize and analyze healthcare data from various sources. The collaborative evaluation of MSK-IMPACT® and MSK-ACCESS® on the DNBSEQ-T1+ platform revealed impressive concordance with other sequencing systems, achieving high alignment in variant calls and allele frequencies, while also minimizing background noise and reducing turnaround times.
The implications of this partnership extend far beyond technological enhancement; it signifies a leap toward promoting comprehensive genomic profiling pathways suitable for clinical laboratories and cancer centers worldwide. As this collaboration unfolds, it promises to not only enrich the capabilities of health institutions but also support drug developers in their quest for innovative treatments.
For those attending the AMP Annual Meeting from November 11–15, 2025, there will be opportunities to learn more about these revolutionary tools and insights at the Complete Genomics Booth 1210 and SOPHiA GENETICS Booth 921. Further information is also available through their respective websites, where they outline their full range of services and technological offerings.
This partnership is more than just a technical alliance; it's a powerful step toward reshaping precision medicine. With the integration of AI-driven analytics and cutting-edge genomic sequencing, Complete Genomics and SOPHiA GENETICS are paving the way for a future where precision oncology is accessible globally, heralding a new era in patient care and cancer treatment strategies.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.